首页 | 本学科首页   官方微博 | 高级检索  
检索        


Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour
Authors:Gessi Stefania  Fogli Eleonora  Sacchetto Valeria  Varani Katia  Merighi Stefania  Leung Edward  Lennan Stephen Mac  Borea Pier Andrea
Institution:a Department of Clinical and Experimental Medicine, Pharmacology Unit and Interdisciplinary Center for the Study of Inflammation, Ferrara, Italy
b King Pharmaceutical, Inc., Research and Development, Cary, NC, United States
Abstract:Thermodynamic parameters ΔG°, ΔH° and ΔS° of the binding equilibrium of 12 ligands (six agonists and six antagonists) to the A2B adenosine receptor subtype have been determined by affinity measurements carried out on HEK 293 cells stably transfected with human A2B adenosine receptors at six different temperatures (4, 10, 15, 20, 25, 30 °C) and van’t Hoff plot analysis have been performed. Affinity constants were obtained from saturation experiments of 3H]MRE 2029-F20 or by its displacement in inhibition assays for the other compounds. van’t Hoff plots were essentially linear in the temperature range investigated, showing that the ΔCp° of the binding equilibrium is nearly zero. Thermodynamic parameters are in the range 7 ≤ ΔH° ≤ 23 kJ mol−1and 123 ≤ ΔS° ≤ 219 J K−1 mol−1 for agonists and −40 ≤ ΔH° ≤ −20 kJ mol−1 and 10 ≤ ΔS° ≤ 91 J K−1 mol−1 for antagonists indicating that agonistic binding is always totally entropy-driven while antagonistic binding is enthalpy and entropy-driven. In the −TΔS° versus ΔH° plot the thermodynamic data are clearly arranged in separate clusters for agonists and antagonists, which, therefore, turn out to be thermodynamically discriminated.
Keywords:AB-MECA  4-aminobenzyl-5&prime  -N-methylcarboxamidoadenosine  CGS 21680  2-[p-(carboxyethyl)-phenethylamino]-NECA  CGS 15943  5-amino-9-chloro-2-(furyl)1  2  4-triazolo[1  5-c]quinazoline  CHA  N6-cyclohexyladenosine  Cl-IB-MECA  N6(3-iodobenzyl)2-chloroadenosine-5&prime  N-methyluronamide  Compound 24  d-ribofuranuronamide" target="_blank">1-deoxy-1-[6-{4-[(phenylcarbamoyl)-methoxy]phenylamino}-9H-purin-9-yl]-N-ethyl-β-d-ribofuranuronamide  Compound 34  d-ribofuranuronamide" target="_blank">1-deoxy-1-[6-{4-[(4-tert-butyl-phenylcarbamoyl)-methoxyl-phenylamino}-9H-purin-9-yl]-N-ethyl-β-d-ribofuranuronamide  Compound 17b  N-[5-(2  6-dioxo-1  3-dipropyl-2  3  6  7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]-2-phenyl-acetamide  Compound 21b  2-(4-benzyloxy-phenyl)-N-[5-(2  6-dioxo-1  3-dipropyl-2  3  6  7-tetrahydro-1H-purin-8yl)-1-methyl-1H-pyrazol-3-yl]-acetamide  CPA  N6-cyclopentyladenosine  CPT  8-cyclopentylxanthine  DPCPX  1  3-dipropyl-8-cyclopentyl-xanthine  DPSPX  1  3-dipropyl-8-sulfophenyl-xanthine  hHEK293-A2B  HEK293 cells transfected with human A2B adenosine receptor  IB-MECA  N6-(3-iodobenzyl) adenosine-5&prime  -N-methyluronamide  IBMX  3-isobutyl-1-methylxanthine  MRE 2029-F20  N-benzo[1  3]dioxol-5-yl-2-[5-(1  3-dipropyl-2  6-dioxo-2  3  6  7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-acetamide]  MRE 3008-F20  5-N-(4-methoxyphenylcarbamoyl)-amino-8-propyl-2-(2-furyl)-pyrazolo[4  3e]-1  2  4triazolo[1  5c]pyrimidine  MRE 3020-F20  5-N-(3-chlorophenylcarbamoyl)-amino-8-ethyl-2(2-furyl)pyrazolo[4  3e]1  2  4triazolo[1  5c]pyrimidine  MRE 3005-F20  5-N-(4-methoxyphenylcarbamoyl)amino-8-phenyl-ethyl-2-(2-furyl)-pyrazolo-[4  3e]1  2  4-triazolo[1  5c]-pyrimidine  NECA  5&prime  -N-ethyl-carboxamidoadenosine  8-PT  8-phenyltheophylline  R-PIA  R(&minus  )-N6-(2-phenyl-isopropyl)adenosine  SCH 58261  5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4  3-e]-1  2  4-triazolo[1  5-c]-pyrimidine  SCH 63390  5-amino-7-(3-phenylpropyl)-2-(2-furyl)-pyrazolo[4  3-e]-1  2  4-triazolo[1  5-c]pyrimidine  S-PIA  S(&minus  )N6-(2-phenyl-isopropyl)adenosine  ZM  241385 (4-(2-[7-amino-2-(2-furyl)-[1  2  4]triazolo-[2  32][1  3  6]triazinyl-amino]ethyl)-phenol)
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号